- Investing Ideas
- /
- Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED May 18, 2024
Companies with a Value score of at least 3, ordered by Value score
19 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
GILD | US$18,660.50 | 4.9% | 91.5% | US$84.4b | US$22,851.25 | PE173.9x | E36.5% | 4.5% | ||
BMY | US$16,212.50 | 0.3% | 49.3% | US$89.3b | US$19,587.02 | PS2x | E44.7% | 5.5% | ||
BIIB | US$19,617.00 | 6.4% | 67.8% | US$33.6b | US$24,326.29 | PE28.8x | E17.8% | n/a | ||
MRNA | US$7,900.00 | 8.2% | n/a | US$50.9b | US$8,233.63 | PS9.9x | E68.8% | n/a | ||
BIIBD | US$16.25 | 0% | n/a | US$33.6b | US$20.15 | PE28.8x | E17.8% | n/a | ||
NVSD | CHF24.25 | 0% | -10.8% | CHF190.5b | CHF25.46 | PE23x | E10.0% | 3.5% | ||
GSKD | UK£12.00 | 0% | n/a | UK£72.4b | UK£13.74 | PE16.1x | E12.2% | 3.3% | ||
NVS | CHF28,427.50 | 3.0% | 128.2% | CHF190.5b | CHF29,843.46 | PE23x | E10.0% | 3.5% | ||
GILDD | US$18.30 | 5.8% | -10.7% | US$84.4b | US$22.41 | PE173.9x | E36.5% | 4.5% | ||
GSK | UK£12,400.00 | 2.2% | 183.3% | UK£72.4b | UK£14,197.41 | PE16.1x | E12.2% | 3.3% | ||
JNJ | US$11,385.50 | 5.5% | 117.9% | US$372.2b | US$12,756.73 | PE21.8x | E6.9% | 3.2% | ||
AMGND | US$11.40 | 6.5% | 36.8% | US$167.6b | US$11.46 | PE44.5x | E17.9% | 2.9% | ||
DJNJ3 | US$1,210.00 | 0% | 113.4% | US$372.2b | US$1,355.73 | PE21.8x | E6.9% | 3.2% | ||
ABBVD | US$16.65 | -7.5% | 10.6% | US$293.9b | US$18.23 | PE49.4x | E23.3% | 3.7% | ||
PFE | US$7,890.50 | 4.4% | 73.7% | US$162.3b | US$8,799.17 | PS3x | E28.9% | 5.9% | ||
JNJD | US$10.90 | 4.8% | -0.9% | US$372.2b | US$12.21 | PE21.8x | E6.9% | 3.2% | ||
AMGN | US$11,501.50 | 3.1% | 213.1% | US$167.6b | US$11,560.22 | PE44.5x | E17.9% | 2.9% | ||
PFED | US$7.46 | 2.2% | -21.7% | US$162.3b | US$8.32 | PS3x | E28.9% | 5.9% | ||
ABBV | US$18,388.00 | 6.3% | 155.9% | US$293.9b | US$20,138.23 | PE49.4x | E23.3% | 3.7% |
Page 1 of 1